|
Hyperlipidemia
|
0.500 |
Biomarker
|
disease |
BEFREE |
Familial combined hyperlipidemia or FCHL is one of the most common genetic causes of hyperlipidemia and is associated with elevation of cholesterol, triglycerides or both, and increased serum apolipoprotein B (apoB).
|
31725952 |
2020 |
|
Hyperlipidemia
|
0.500 |
Biomarker
|
disease |
BEFREE |
Fasting Apolipoprotein B48 (ApoB48) is reported to be a well surrogate marker for postprandial lipidemia and have been repeatedly associated with cardiovascular disease.
|
30842592 |
2019 |
|
Hyperlipidemia
|
0.500 |
Biomarker
|
disease |
BEFREE |
Liraglutide Reduces Postprandial Hyperlipidemia by Increasing ApoB48 (Apolipoprotein B48) Catabolism and by Reducing ApoB48 Production in Patients With Type 2 Diabetes Mellitus.
|
30026275 |
2018 |
|
Hyperlipidemia
|
0.500 |
Biomarker
|
disease |
BEFREE |
The multivariate analysis showed that age (OR = 2.62, 95%CI: 1.51-4.56, P = 0.001), hyperlipidemia (OR = 1.89, 95%CI: 1.07-3.36, P = 0.029), high-density lipoprotein cholesterol (HDL-C) (OR = 0.46, 95%CI: 0.24-0.87, P = 0.02), the ratio of total cholesterol to high-density lipoproteincholesterol (TC/HDL-C) (OR = 0.69, 95%CI: 0.50-0.94, P = 0.02), apolipoprotein B (apoB) (OR = 3.08, 95%CI: 1.50-6.32, P = 0.002), and adiponectin (OR = 0.37, 95%CI: 0.19-0.74, P = 0.005) were independently associated with the presence of high risk plaques.
|
29859480 |
2018 |
|
Hyperlipidemia
|
0.500 |
Biomarker
|
disease |
BEFREE |
Apolipoprotein B (ApoB), as the only essential scaffolding protein in the assembly of very-low-density lipoproteins, is a target to treat hyperlipidemia and atherosclerosis.
|
28336556 |
2017 |
|
Hyperlipidemia
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Association between polymorphisms in the APOB gene and hyperlipidemia in the Chinese Yugur population.
|
28902930 |
2017 |
|
Hyperlipidemia
|
0.500 |
Biomarker
|
disease |
BEFREE |
Atorvastatin lowered total cholesterol, LDL-C, non HDL-C and apolipoprotein B in HIV-infected youth with ART-associated hyperlipidemia.
|
27749649 |
2017 |
|
Hyperlipidemia
|
0.500 |
Biomarker
|
disease |
BEFREE |
Diagnosis of dysbetalipoproteinaemia should be considered in mixed hyperlipidaemias for which the apolipoprotein B concentration is relatively low in relation to the total cholesterol concentration or when there is significant disparity between the calculated LDL and directly measured LDL cholesterol concentrations.
|
24405372 |
2014 |
|
Hyperlipidemia
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
This is the first report focusing on a possible association of apoB VNTR polymorphism with nephrotic hyperlipidemia.
|
23546960 |
2013 |
|
Hyperlipidemia
|
0.500 |
Biomarker
|
disease |
BEFREE |
Microsomal triglyceride transfer protein (MTP) plays a key role in the lipidation of nascent apoB and the secretion of apoB-containing lipoproteins enriched with triglycerides and is thus a promising target for the treatment of hyperlipidemia.
|
24201112 |
2013 |
|
Hyperlipidemia
|
0.500 |
Biomarker
|
disease |
BEFREE |
Mipomersen displayed dose-dependent efficacy in lowering LDL-C, ApoB, triglycerides, total cholesterol and other low-density lipoproteins in healthy volunteers with mild hyperlipidemia.
|
22348914 |
2011 |
|
Hyperlipidemia
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Comparison of lipid profiles in relation to APOB EcoRI polymorphism in obese children with hyperlipidemia.
|
20133978 |
2010 |
|
Hyperlipidemia
|
0.500 |
Biomarker
|
disease |
BEFREE |
Apolipoprotein B-100 (apoB-100) has been implicated in hyperlipidemia, which contributes to the pathogenesis of vascular disorders.
|
19409916 |
2009 |
|
Hyperlipidemia
|
0.500 |
Biomarker
|
disease |
CTD_human |
Combined hyperlipidemia results from overproduction of hepatically synthesized apolipoprotein B in very low-density lipoproteins in association with reduced lipoprotein lipase activity.
|
17658632 |
2008 |
|
Hyperlipidemia
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
In FCHL relatives (n = 618) and spouses (n = 297), prevalence data of hyperlipidemia and high apolipoprotein B levels and their age and gender-corrected odds ratios (ORs) were calculated for sex-adjusted categories of waist-to-hip ratio (WHR), waist circumference, and BMI.
|
15687407 |
2004 |
|
Hyperlipidemia
|
0.500 |
GeneticVariation
|
disease |
LHGDN |
A new but frequent mutation of apoB-100-apoB His3543Tyr.
|
15135245 |
2004 |
|
Hyperlipidemia
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
This minireview is aimed to discuss the impact of apoB-100 and its structural variants on plasma lipid metabolism and development of hyperlipidemia.
|
11551138 |
2001 |
|
Hyperlipidemia
|
0.500 |
Biomarker
|
disease |
BEFREE |
Hammerhead ribozyme as a therapeutic agent for hyperlipidemia: production of truncated apolipoprotein B and hypolipidemic effects in a dyslipidemia murine model.
|
11096445 |
2000 |
|
Hyperlipidemia
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Hyperlipidaemia associated with genetic variation in the apolipoprotein B gene.
|
7670750 |
1995 |
|
Hyperlipidemia
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Independent mutations at codon 3500 of the apolipoprotein B gene are associated with hyperlipidemia.
|
7627691 |
1995 |
|
Hyperlipidemia
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
The only significant differences found among the groups, regardless of the presence of hyperlipemia, were the increased levels of total and high-density lipoprotein phospholipids, and lower levels of apolipoprotein B, found in the group with xanthelasmas.
|
3401027 |
1988 |
|
Hyperlipidemia
|
0.500 |
Biomarker
|
disease |
BEFREE |
Metabolism of very low density lipoproteins in hyperlipidaemia: studies of apolipoprotein B kinetics in man.
|
177296 |
1976 |
|
Hyperlipidemia
|
0.500 |
Biomarker
|
disease |
HPO |
|
|
|